Bionano Stock Financials


USD 2.12  0.04  1.85%   

We suggest to use analysis of Bionano Genomics fundamentals to see if markets are presently mispricing the company. We were able to analyze and collect data for thirty-six available fundamental indicators for Bionano Genomics, which can be compared to its rivals. To ensure the equity is not overpriced, please confirm all Bionano Genomics financials, including its price to sales, book value per share, working capital, as well as the relationship between the cash and equivalents and number of employees . Please also double-check Bionano Genomics price to earning to validate the company can sustain itself down the road. Use Bionano Genomics to protect your portfolios against small market fluctuations. Benchmarks are essential to demonstrate the utility of optimization algorithms. The stock experiences a somewhat bearish sentiment, but the market may correct it shortly. Check odds of Bionano Genomics to be traded at $2.06 in 90 days.
With this module, you can analyze Bionano financials for your investing period. You should be able to track the changes in Bionano Genomics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Understanding current and past Bionano Genomics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bionano Genomics' financial statements are interrelated, with each one affecting the others. For example, an increase in Bionano Genomics' assets may result in an increase in income on the income statement.
Chance Of Financial Distress
Less than 23
Bionano Genomics has less than 23 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Bionano Genomics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Bionano Genomics' official financial statements usually reflect Bionano Genomics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bionano Genomics. For example, before you start analyzing numbers published by Bionano accountants, it's critical to develop an understanding of what Bionano Genomics' liquidity, profitability, and earnings quality are in the context of the Life Sciences Tools & Services space in which it operates.
Please note, the presentation of Bionano Genomics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bionano Genomics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bionano Genomics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bionano Genomics. Please utilize our Beneish M Score to check the likelihood of Bionano Genomics' management to manipulate its earnings.

Bionano Genomics Company Summary

Bionano Genomics competes with Super Micro, HP, AstroNova, Insight Enterprises, and JPMorgan Active. Bionano Genomics, Inc. provides genome analysis software solutions. The company was founded in 2003 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 299 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
Business Address9540 Towne Centre
SectorLife Sciences Tools & Services
IndustryHealth Care
BenchmarkNYSE Composite
Phone858 888 7600
CurrencyUSD - US Dollar
You should never invest in Bionano Genomics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bionano Stock, because this is throwing your money away. Analyzing the key information contained in Bionano Genomics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Bionano Genomics Key Financial Ratios

Generally speaking, Bionano Genomics' financial ratios allow both analysts and investors to convert raw data from Bionano Genomics' financial statements into concise, actionable information that can be used to evaluate the performance of Bionano Genomics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Bionano Genomics reports annually and quarterly.

Bionano Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bionano Genomics's current stock value. Our valuation model uses many indicators to compare Bionano Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bionano Genomics competition to find correlations between indicators driving Bionano Genomics's intrinsic value. More Info.
Bionano Genomics is number one stock in gross profit category among related companies. It is number one stock in return on asset category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bionano Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bionano Genomics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bionano Genomics' earnings, one of the primary drivers of an investment's value.

Bionano Genomics Systematic Risk

Bionano Genomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bionano Genomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was two with a total number of output elements of fifty-nine. The Beta measures systematic risk based on how returns on Bionano Genomics correlated with the market. If Beta is less than 0 Bionano Genomics generally moves in the opposite direction as compared to the market. If Bionano Genomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bionano Genomics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bionano Genomics is generally in the same direction as the market. If Beta > 1 Bionano Genomics moves generally in the same direction as, but more than the movement of the benchmark.

About Bionano Genomics Financials

What exactly are Bionano Genomics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Bionano Genomics' income statement, its balance sheet, and the statement of cash flows. Potential Bionano Genomics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Bionano Genomics investors may use each financial statement separately, they are all related. The changes in Bionano Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bionano Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Bionano Genomics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Bionano has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Bionano Genomics December 9, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Bionano Genomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bionano Genomics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bionano Genomics based on widely used predictive technical indicators. In general, we focus on analyzing Bionano Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bionano Genomics's daily price indicators and compare them against related drivers.
Downside Deviation5.73
Information Ratio(0.002939)
Maximum Drawdown32.56
Value At Risk(8.66)
Potential Upside10.37
Continue to Trending Equities. Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine Bionano Genomics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.